Restoring Nerve Function
Solaxa is a clinical-ready biopharmaceutical company developing treatments for
rare neurodegenerative disease and acute nerve injuries.
We are pursuing both novel and reformulated drugs to
restore nerve function by targeting ion channels.
Our Company: By The Numbers
2
Investigator-initiated IND trials funded & enrolling
15
6 issued and 9 pending US, EU, Canada patents exclusively licensed
115
Cerebellar ataxia patients studied with drug
$8M+
Non-dilutive NIH & DoD grants to co-founders
20+
Peer-reviewed publications by co-founders
World-Class Leadership
We’ve assembled an experienced management team and advisors with expertise from small and large biopharma to generate an innovative pipeline addressing the unmet needs in neurology.
We are passionate scientists, clinicians and commercial experts dedicated to develop therapies for patients globally suffering from nerve diseases and injuries.
Pipeline
TARGET | INDICATION | PROGRAM | PRECLINICAL | PHASE I | PHASE II | PHASE III | APPROVAL |
---|---|---|---|---|---|---|---|
Ataxia | Late-Onset | SLX-100 | 2026 | ||||
Pediatric | SLX-200 | 2028 | |||||
Nerve Injuries | CIPN | SLX-300 | 2029 | ||||
Trauma | SLX-400 | TBD |